Career
Daniel D. Von Hoff, M.D., F.A.C.P., has devoted his career to translational medicine, which is defined as movement of new therapies from the research institution into patient care. He currently serves as Physician-in-Chief and Distinguished Professor of the Translational Genomics Research Institute (TGen); Professor of Medicine at both Mayo Clinic, Scottsdale and the University of Arizona College of Medicine; and Chief Scientific Officer at Scottsdale Healthcare and US Oncology and Clinical Professor of Medicine at the University of Arizona. In addition, he provides expertise as a founder or medical/scientific advisor to a broad range of companies working toward a cure for cancer.
After graduating cum laude from Carroll University, Dr. Von Hoff received his M.D. from Columbia University College of Physicians and Surgeons. He completed his internship and residency in internal medicine at the University of California, San Francisco, then completed a medical oncology fellowship at the National Cancer Institute. Dr. Von Hoff then moved to the University of Texas Health Science Center at San Antonio, where he rose to Professor in the Department of Medicine and the Department of Cellular and Structural Biology. In 1989, Dr. Von Hoff became the Founding Director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio. In 1999, he became Director of the Cancer Center and Professor of Medicine at the University of Arizona.
Dr. Von Hoff has served as editor of numerous scientific publications. He is founder and Editor Emeritus of “Investigational New Drugs: The Journal of New Anticancer Agents” as well as the founding and current Editor-in-Chief of “Molecular Cancer Therapeutics”. Previously he was the associate editor of “Cancer Research” and “Clinical Cancer Research”. Dr. Von Hoff has also served on the editorial boards of the “American Journal of Medicine”, “Anticancer Drugs”, “Oncology”, “Annals of Oncology”, and nine other scientific journals.
He is a Fellow of the American College of Physicians, and has been a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and AACR, as well as a member of the FDA's Oncology Drug Advisory Committee (ODAC).
He co-founded ILEX™ Oncology, Inc. (acquired by Genzyme). The ILEX team got two 2 new anti-cancer agents approved by the FDA, including Clolar (clofarabine) for children with leukemia and Campath (alemtuzumab) for patients with chronic lymphocytic leukemia. Campath is also now included in trials for patients with multiple sclerosis.
Read more about this topic: Daniel Von Hoff
Famous quotes containing the word career:
“It is a great many years since at the outset of my career I had to think seriously what life had to offer that was worth having. I came to the conclusion that the chief good for me was freedom to learn, think, and say what I pleased, when I pleased. I have acted on that conviction... and though strongly, and perhaps wisely, warned that I should probably come to grief, I am entirely satisfied with the results of the line of action I have adopted.”
—Thomas Henry Huxley (1825–95)
“I began my editorial career with the presidency of Mr. Adams, and my principal object was to render his administration all the assistance in my power. I flattered myself with the hope of accompanying him through [his] voyage, and of partaking in a trifling degree, of the glory of the enterprise; but he suddenly tacked about, and I could follow him no longer. I therefore waited for the first opportunity to haul down my sails.”
—William Cobbett (1762–1835)
“Whether lawyer, politician or executive, the American who knows what’s good for his career seeks an institutional rather than an individual identity. He becomes the man from NBC or IBM. The institutional imprint furnishes him with pension, meaning, proofs of existence. A man without a company name is a man without a country.”
—Lewis H. Lapham (b. 1935)